Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan:128:351-365.
doi: 10.1016/j.neuropharm.2017.10.032. Epub 2017 Oct 26.

Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders

Robert F Bruns  1 , Stephen N Mitchell  2 , Keith A Wafford  2 , Alex J Harper  2 , Elaine A Shanks  2 , Guy Carter  2 , Michael J O'Neill  2 , Tracey K Murray  2 , Brian J Eastwood  2 , John M Schaus  1 , James P Beck  1 , Junliang Hao  1 , Jeffrey M Witkin  1 , Xia Li  1 , Eyassu Chernet  1 , Jason S Katner  1 , Hong Wang  1 , John W Ryder  1 , Meghane E Masquelin  1 , Linda K Thompson  1 , Patrick L Love  1 , Deanna L Maren  1 , Julie F Falcone  1 , Michelle M Menezes  1 , Linli Zhang  3 , Charles R Yang  3 , Kjell A Svensson  4
Affiliations
Free article

Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders

Robert F Bruns et al. Neuropharmacology. 2018 Jan.
Free article

Abstract

DETQ, an allosteric potentiator of the dopamine D1 receptor, was tested in therapeutic models that were known to respond to D1 agonists. Because of a species difference in affinity for DETQ, all rodent experiments used transgenic mice expressing the human D1 receptor (hD1 mice). When given alone, DETQ reversed the locomotor depression caused by a low dose of reserpine. DETQ also acted synergistically with L-DOPA to reverse the strong hypokinesia seen with a higher dose of reserpine. These results indicate potential as both monotherapy and adjunct treatment in Parkinson's disease. DETQ markedly increased release of both acetylcholine and histamine in the prefrontal cortex, and increased levels of histamine metabolites in the striatum. In the hippocampus, the combination of DETQ and the cholinesterase inhibitor rivastigmine increased ACh to a greater degree than either agent alone. DETQ also increased phosphorylation of the AMPA receptor (GluR1) and the transcription factor CREB in the striatum, consistent with enhanced synaptic plasticity. In the Y-maze, DETQ increased arm entries but (unlike a D1 agonist) did not reduce spontaneous alternation between arms at high doses. DETQ enhanced wakefulness in EEG studies in hD1 mice and decreased immobility in the forced-swim test, a model for antidepressant-like activity. In rhesus monkeys, DETQ increased spontaneous eye-blink rate, a measure that is known to be depressed in Parkinson's disease. Together, these results provide support for potential utility of D1 potentiators in the treatment of several neuropsychiatric disorders, including Parkinson's disease, Alzheimer's disease, cognitive impairment in schizophrenia, and major depressive disorder.

Keywords: D1 receptor; DETQ (PubChem CID 117720272.); Dopamine; Eye-blink; L-DOPA (PubChem CID 6407); Parkinson's disease; Positive allosteric modulator; Potentiator; SCH39166 (PubChem CID 107930); SKF 82958 (PubChem CID 1255).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms